Logo image of MRVI

MARAVAI LIFESCIENCES HLDGS-A (MRVI) Stock Fundamental Analysis

USA - NASDAQ:MRVI - US56600D1072 - Common Stock

3.37 USD
-0.15 (-4.26%)
Last: 10/21/2025, 4:01:41 PM
3.37 USD
0 (0%)
After Hours: 10/21/2025, 4:01:41 PM
Fundamental Rating

2

MRVI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. While MRVI seems to be doing ok healthwise, there are quite some concerns on its profitability. MRVI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MRVI had negative earnings in the past year.
MRVI had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MRVI reported negative net income in multiple years.
Each year in the past 5 years MRVI had a positive operating cash flow.
MRVI Yearly Net Income VS EBIT VS OCF VS FCFMRVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

Looking at the Return On Assets, with a value of -21.71%, MRVI is doing worse than 68.42% of the companies in the same industry.
Looking at the Return On Equity, with a value of -73.24%, MRVI is doing worse than 75.44% of the companies in the same industry.
Industry RankSector Rank
ROA -21.71%
ROE -73.24%
ROIC N/A
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
MRVI Yearly ROA, ROE, ROICMRVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

With a Gross Margin value of 29.11%, MRVI is not doing good in the industry: 71.93% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of MRVI has declined.
The Profit Margin and Operating Margin are not available for MRVI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
MRVI Yearly Profit, Operating, Gross MarginsMRVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

MRVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRVI has more shares outstanding than it did 1 year ago.
MRVI has less shares outstanding than it did 5 years ago.
The debt/assets ratio for MRVI has been reduced compared to a year ago.
MRVI Yearly Shares OutstandingMRVI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
MRVI Yearly Total Debt VS Total AssetsMRVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of 1.18, we must say that MRVI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.18, MRVI perfoms like the industry average, outperforming 40.35% of the companies in the same industry.
A Debt/Equity ratio of 1.20 is on the high side and indicates that MRVI has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.20, MRVI is doing worse than 77.19% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.2
Debt/FCF N/A
Altman-Z 1.18
ROIC/WACCN/A
WACC11.7%
MRVI Yearly LT Debt VS Equity VS FCFMRVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 5.16 indicates that MRVI has no problem at all paying its short term obligations.
The Current ratio of MRVI (5.16) is better than 73.68% of its industry peers.
MRVI has a Quick Ratio of 4.49. This indicates that MRVI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.49, MRVI is in the better half of the industry, outperforming 71.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.16
Quick Ratio 4.49
MRVI Yearly Current Assets VS Current LiabilitesMRVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for MRVI have decreased strongly by -1100.00% in the last year.
MRVI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -22.53%.
Measured over the past years, MRVI shows a quite strong growth in Revenue. The Revenue has been growing by 12.61% on average per year.
EPS 1Y (TTM)-1100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-391.94%
Revenue 1Y (TTM)-22.53%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-35.43%

3.2 Future

MRVI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -20.59% yearly.
MRVI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.36% yearly.
EPS Next Y-213.57%
EPS Next 2Y-41.15%
EPS Next 3Y-1.39%
EPS Next 5Y-20.59%
Revenue Next Year-26.17%
Revenue Next 2Y-11%
Revenue Next 3Y-4.63%
Revenue Next 5Y0.36%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MRVI Yearly Revenue VS EstimatesMRVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
MRVI Yearly EPS VS EstimatesMRVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 1 1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRVI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRVI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRVI Price Earnings VS Forward Price EarningsMRVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRVI Per share dataMRVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.15%
EPS Next 3Y-1.39%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRVI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARAVAI LIFESCIENCES HLDGS-A

NASDAQ:MRVI (10/21/2025, 4:01:41 PM)

After market: 3.37 0 (0%)

3.37

-0.15 (-4.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners76.4%
Inst Owner Change0%
Ins Owners5.33%
Ins Owner Change39.65%
Market Cap860.56M
Analysts76.47
Price Target4.08 (21.07%)
Short Float %13.23%
Short Ratio10.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.2%
Min EPS beat(2)-10.61%
Max EPS beat(2)-9.8%
EPS beat(4)0
Avg EPS beat(4)-55.61%
Min EPS beat(4)-154.98%
Max EPS beat(4)-9.8%
EPS beat(8)2
Avg EPS beat(8)-46.33%
EPS beat(12)4
Avg EPS beat(12)-39.93%
EPS beat(16)8
Avg EPS beat(16)-25.3%
Revenue beat(2)1
Avg Revenue beat(2)1.24%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)4.37%
Revenue beat(4)1
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-5.38%
Max Revenue beat(4)4.37%
Revenue beat(8)4
Avg Revenue beat(8)-0.27%
Revenue beat(12)4
Avg Revenue beat(12)-1.33%
Revenue beat(16)7
Avg Revenue beat(16)-0.22%
PT rev (1m)-3.03%
PT rev (3m)-31.86%
EPS NQ rev (1m)-4.63%
EPS NQ rev (3m)-25.85%
EPS NY rev (1m)1.86%
EPS NY rev (3m)-7.24%
Revenue NQ rev (1m)0.67%
Revenue NQ rev (3m)-1.93%
Revenue NY rev (1m)0.16%
Revenue NY rev (3m)-1.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.99
P/FCF N/A
P/OCF N/A
P/B 3.24
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.85
BVpS1.04
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.71%
ROE -73.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.11%
FCFM N/A
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 1.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 47.92%
Cap/Sales 11.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.16
Quick Ratio 4.49
Altman-Z 1.18
F-Score4
WACC11.7%
ROIC/WACCN/A
Cap/Depr(3y)93.62%
Cap/Depr(5y)87.93%
Cap/Sales(3y)12.22%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-391.94%
EPS Next Y-213.57%
EPS Next 2Y-41.15%
EPS Next 3Y-1.39%
EPS Next 5Y-20.59%
Revenue 1Y (TTM)-22.53%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-35.43%
Revenue Next Year-26.17%
Revenue Next 2Y-11%
Revenue Next 3Y-4.63%
Revenue Next 5Y0.36%
EBIT growth 1Y-148.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1991.95%
EBIT Next 3Y183.62%
EBIT Next 5Y118.38%
FCF growth 1Y-116.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-106.74%
OCF growth 3Y-72.74%
OCF growth 5Y-20.9%